Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 14/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 14/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19697969 | 0.88 | GABRG2 (0.47) | GABRG2GABRB3GABRA5CDK9GRIN2B | |
| SCHEMBL21026237 | 0.78 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL17678028 | 0.77 | GABRG2 (0.50) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL19703419 | 0.76 | DYRK1A (0.44) | — | |
| SCHEMBL17678092 | 0.75 | GABRG2 (0.50) | GABRG2GABRB3GABRA5CDK9GRIN2B | |
| SCHEMBL12938768 | 0.74 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL4249780 | 0.71 | GABRG2 (0.47) | GABRG2GABRB3GABRA5CDK9 | |
| SCHEMBL12767960 | 0.71 | NPSR1 (0.49) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL18211613 | 0.71 | MAPT (0.42) | MEN1KMT2A | |
| SCHEMBL19703420 | 0.71 | BRD4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | PIK3R3, PIK3R5, PIK3R1 | GABRG2 1287/4885GABRB3 768/4885GABRA5 1562/4885 |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | PIK3R3, PIK3R5, PIK3R1 | GABRG2 1287/4885GABRB3 768/4885GABRA5 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.